A cytosine analog that confers enhanced potency to antisense oligonucleotides

by Flanagan, W. Michael, Wolf, John J., Olson, Peter, Grant, Debbie, Lin, Kuei-Ying, Wagner, Richard W., Matteucci, Mark D.
Published 1999

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

by Meng, Fanying, Bhupathi, Deepthi, Sun, Jessica D, Liu, Qian, Ahluwalia, Dharmendra, Wang, Yan, Matteucci, Mark D, Hart, Charles P
Published in BMC Cancer (2015)

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

by Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Ferraro, Damien J., Wang, Yan, Jung, Don, Matteucci, Mark D., Hart, Charles P.
Published in Cancer Biol Ther (2016)

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

by Sun, Jessica D, Ahluwalia, Dharmendra, Liu, Qian, Li, Wenwu, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Matteucci, Mark D, Hart, Charles P
Published in Am J Cancer Res (2015)

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

by Liu, Qian, Sun, Jessica D., Wang, Jingli, Ahluwalia, Dharmendra, Baker, Amanda F., Cranmer, Lee D., Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W. Steve, Curd, John G., Matteucci, Mark D., Hart, Charles P.
Published 2012